Cataract Clinical Trial
Official title:
Ocular Surface and Corneal Morphological Changes After the Cataract Surgery and Associations With Inflammatory Biomarkers
NCT number | NCT06298890 |
Other study ID # | SASKAT |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 2024 |
Est. completion date | September 2027 |
This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | September 2027 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 90 Years |
Eligibility | Inclusion Criteria: - Cataract patients from 50 to 90 years old who underwent uncomplicated phacoemulsification performed by one (and same) experienced surgeon. - Patients with no underlying ocular surface diseases (keratitis, keratoconjunctivitis and others). - Patients who previously did not undergo any ophthalmic surgery. Exclusion Criteria: - Patient expressed his wish to not participate in the study or discontinue it when already enrolled. - Severe dry eye disease diagnosed with OSDI/DEQ-5 and at least one of the following tests: TBUT less than 10 seconds, tear osmolarity higher than 308 mOsm/l or positive corneal staining. - Glaucoma. - Diabetes mellitus. - Systemic connective tissue disease, autoimmune disease. - Neurologic conditions including stroke, Bell's palsy, Parkinson's, trigeminal nerve dysfunction. - Patients who underwent refractive surgery (LASIK or PRK). - Contact lens users. - One or more of the following concomitant medications: psychiatric medicines, antihistamines and/or hormonal replacement. - Patients who are already regularly using topical drops or ointments. |
Country | Name | City | State |
---|---|---|---|
Lithuania | Lithuanian University of Health Sciences | Kaunas |
Lead Sponsor | Collaborator |
---|---|
Lithuanian University of Health Sciences | Santen Oy |
Lithuania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of ocular surface changes following cataract surgery | Measured using LacryDiag (Quantel Medical, France), parameters included: non-invasive tear break up time, the height of the tear meniscus, interferometry. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Primary | Evaluation of the cornea morphology | Evaluated performing confocal corneal microscopy, parameters include: corneal nerve fibre number and density. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Primary | Evaluation of matrix metalloproteinase-9 (MMP-9) levels in patients' tears | Matrix metalloproteinase 9 is an inflammatory biomarker that has been shown to be elevated in the tears of dry eye disease (DED) patients. MMP-9 testing is a valuable diagnostic tool in identifying the presence of ocular surface inflammation in DED patients. MMP-9 level results are classified as positive or negative. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Primary | Evaluation of tear osmolarity | Evaluated with the TearLab Osmolarity System. Increased osmolarity indicates dry eye. Values greater than 300 mOsm/kg are suggestive of dry eye. From 300 mOsm/L to 320 mOsm/L, is graded as mild; from 320 mOsm/L to 340 mOsm/L, is graded as moderate; and greater than 340 mOsm/L, is graded as severe. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Primary | Evaluation of tear cytokine levels | Interleukin -2, -6, -1ß, tumour necrosis factor a (TNFa), interferon-gamma (IFN-?) levels in tears are significantly higher in patients' with dry eye disease (DED) and they correlate with the severity of DED. Cytokine levels in tears will be evaluated using Human Immunotherapy Luminex® Performance Assay 25-plex Fixed Panel System. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Primary | Assessment of central corneal sensitivity | Measured using Cochet-Bonnet aesthesiometer (Luneau; Pruneay-Le-Gillon, France). | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Secondary | Evaluation of potential pain biomarkers in patients' saliva | Pain biomarkers which will be evaluated - soluble tumor necrosis factor-a receptor II (sTNFaRII), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), secretory IgA (SIgA). Pain is a common complaint in both dry eye disease (DED) and post-cataract surgery.
Pain biomarkers will be evaluated using ELISA methods. |
7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Secondary | Dry Eye Questionnaire-5 (DEQ5) 5-item | The DEQ-5 consists of five questions that assess the following: frequency of watery eye, discomfort, and dryness (scored on a 0-4 scale) and late day discomfort and dryness intensity (scored on a 0 -5 scale). | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Secondary | Ocular surface disease index (OSDI) | OSDI is a 12-item questionnaire that assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Secondary | Visual function (VFQ-25) questionnaire | The 25-item questionnaire has several subscale categories that assesses different aspects of health-related quality of life including overall health, overall vision, difficulty with near vision, difficulty with distance vision, limitations in social functioning due to vision, role limitations due to vision, dependency on others due to vision, mental health symptoms due to vision, future expectations for vision, driving difficulties, and pain and discomfort around the eyes | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. | |
Secondary | Visual acuity evaluation (LogMAR) | Mean change from baseline. | 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |